Your AI-Trained Oncology Knowledge Connection!
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).
Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses factors to consider when choosing upfront therapy for patients with chronic lymphocytic leukemia (CLL).
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the toxicities related to stem cell transplantation for patients with mantle cell lymphoma (MCL).
John P. Leonard, MD, professor of Medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).
Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses second-generation BTK inhibitors, such as acalabrutinib and BGB-3111 in chronic lymphocytic leukemia (CLL).
Adrienne A. Phillips, MD, discussed the subtypes of adult T-cell lymphoma/leukemia, the challenges with treating them, and what community oncologists need to know about these patient populations.
Lisa G. Roth, MD, discusses the challenges of treating adolescent and young adult patients with Hodgkin lymphoma and the benefits of having a multidisciplinary approach with this population.
Tsiporah B. Shore, MD, discusses some of these newer advancements related to stem cell transplantation and the challenges with including patients in ethnic populations.
Sarah Rutherford, MD, discusses rare DLBCL subtypes, ongoing research to improve outcomes for these patient populations, and the potential role of CAR T-cell therapy.
Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses risk factors for patients with early-onset colorectal cancer (CRC).
Peter Martin, MD, discusses the evolution of treatment and ongoing research for patients with mantle cell lymphoma.
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).
John P. Leonard, MD, professor of medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the maintenance strategy of rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).
Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the use of prognostic markers in the treatment of patients with chronic lymphocytic leukemia (CLL).
Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian, discusses preferences patients have for their treatment of mantle cell lymphoma (MCL).
John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.
Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the difference in treatment of left- and right-sided tumors in colorectal cancer.
Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.
Manish Shah, MD, discusses ongoing efforts to understand the distinction between early-onset CRC and traditional CRC.
David M. Nanus, MD, discusses evolving therapeutic strategies in the neoadjuvant and adjuvant setting for patients with renal cell carcinoma.
Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses indications of early-onset colorectal cancer (CRC).
Peter Martin, MD, discusses the efficacy of a combination regimen of ibrutinib and palbociclib in the treatment of patients with mantle cell lymphoma.
In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.
In a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.
Peter Martin, MD, associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, predicts future treatment approaches in the field of mantle cell lymphoma (MCL).
David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.
The FDA has approved carfilzomib (Kyprolis) in combination with dexamethasone or with lenalidomide plus dexamethasone for patients with relapsed/refractory multiple myeloma following prior treatment with 1 to 3 lines of therapy
John P. Leonard, MD, discusses the potential for lenalidomide, idelalisib, and ibrutinib in follicular lymphoma, possible combination therapies, and challenges that remain in the treatment of the disease.
Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).
